Mizuho Securities USA LLC Has $10.63 Million Position in Pfizer Inc. (NYSE:PFE)

Mizuho Securities USA LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 367,455 shares of the biopharmaceutical company's stock after selling 69,459 shares during the period. Mizuho Securities USA LLC's holdings in Pfizer were worth $10,634,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in PFE. Marshall Wace LLP lifted its stake in Pfizer by 279.3% during the second quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock valued at $150,481,000 after buying an additional 8,378,173 shares in the last quarter. Swedbank AB purchased a new stake in Pfizer during the first quarter valued at about $172,902,000. International Assets Investment Management LLC purchased a new stake in Pfizer during the third quarter valued at about $146,481,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Pfizer by 164.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock valued at $211,737,000 after buying an additional 4,546,809 shares in the last quarter. Finally, 1832 Asset Management L.P. lifted its position in shares of Pfizer by 24,961.6% in the second quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company's stock worth $69,891,000 after purchasing an additional 2,487,919 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.5 %

Shares of Pfizer stock traded up $0.12 during trading on Thursday, hitting $25.06. 34,540,022 shares of the company were exchanged, compared to its average volume of 38,472,801. The firm has a market capitalization of $142.03 billion, a P/E ratio of 33.65, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm's fifty day moving average price is $28.36 and its 200 day moving average price is $28.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.70%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is 227.03%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research analyst reports. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Finally, UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.92.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the company's stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.